The development of recombinant factor Ⅷ concentrates for clinical application / 国际儿科学杂志

ABSTRACT

Replacement therapy with plasma derived or recombinant F Ⅷ (rFⅧ) concentrates is only effective way to treat hemophilia A.Currently,the first,second and third generation rFⅧ are commercially available.Of the three products,the third generation rFⅧ products are best,because of no additional human or animal plasma proteins at any period.The use of rFⅧ concentrates has greatly improved the safety of replacement therapy in hemophilia A and reduced the risk of blood-borne pathogen transmission.In this article we review the current knowledge about the three rF Ⅷ concentrates,analyzing their main characteristic and their clinical hemostatic efficacy and safety.